Cowen and Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cowen and Company’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,400	Closed	-$22.3K	–	589
2023 Q1	$22.3K	Buy	14,400 +4,400	+44%	+$456K	﹤0.01%	296
2022 Q4	$5.5K	Buy	+10,000	New	+$939K	﹤0.01%	470
2022 Q2	–	Sell	-37,500	Closed	-$46K	–	664
2022 Q1	$46K	Sell	37,500 -20,800	-36%	-$1.74M	﹤0.01%	339
2021 Q4	$12K	Buy	+58,300	New	+$4.81M	﹤0.01%	570
2021 Q3	–	Sell	-10,000	Closed	-$12K	–	606
2021 Q2	$12K	Sell	10,000 -5,000	-33%	-$396K	﹤0.01%	531
2021 Q1	$20K	Sell	15,000 -14,300	-49%	-$1.17M	﹤0.01%	452
2020 Q4	$124K	Buy	29,300 +20,500	+233%	+$1.63M	0.01%	206
2020 Q3	$29K	Buy	+8,800	New	+$890K	﹤0.01%	329

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cowen and Company's BMRN Position: Q1 2024 in Review

Cowen and Company sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 22,865 shares — an estimated $2.2M sold.

Cowen and Company first reported a position in BMRN in Q3 2020 and held it in 6 quarters. The position peaked at $2.2M in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Cowen and Company reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 22,865 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $2.2M.
Cowen and Company first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 6 quarters.
Cowen and Company's BioMarin Pharmaceuticals position peaked at $2.2M in Q4 2023.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.